摘要
目的研究血清乳酸脱氢酶(LDH)和血清β2微球蛋白(β2-MG)对于判断急性髓细胞白血病(AML)预后的价值。方法回顾性分析68例(AML)患者初发、缓解、复发时血清LDH和血清β2-MG水平,分析其疗效及与预后的关系。结果AML各型患者的血LDH和β2-MG水平相同。初发、复发时血LDH和β2-MG水平较缓解时高。血LDH和β2-MG水平低的患者安全缓解(CR)率高,生存期、无病生存期长。血LDH和β2-MG均增高的患者较单项增高或均正常的患者CR率低,生存期、无病生存期短。结论血LDH和β2-MG是AML患者有意义的预后指标,而联合检测对于疗效、预后意义更明显。
Objective To investigate the prognostic values of serum lactate dehydrogenase （LDH） and beta-2 microglobulin （β2-MG） levels in patients with acute myeloid leukemia（AML）. Methods The associations of serum LDH and β2-MG levels at diagnosis, remission and relapse with treatment and prognosis in 68 patients with AML were retrospectively analysed. Results There were no difference in LDH and β2-MG between AML subtypes patients. The level of serum LDH and β2-MG at diagnosis and relapse were much higher than those at remission. Patients with lower level of LDH and β2-MG got higher CR rate and longer term overall survival and disease-free survival. Patients with higher level of both LDH and β2-MG got lower CR rate, shorter term of overall survival and disease-free survival than those with higher level of LDH or β2-MG or those with normal level of LDH and β2-MG. Conclusion LDH and β2-MG is a singifieant prognostic indicator for AML. While combined LDH and β2-MG are more definite for the treatment and diagnosis.
出处
《上海交通大学学报（医学版）》
CAS
CSCD
北大核心
2007年第4期445-447,共3页
Journal of Shanghai Jiao tong University:Medical Science
